14 articles5,908 citations
Doxorubicin Alone versus Intensified Doxorubicin Plus Ifosfamide for First-Line Treatment of Advanced or Metastatic Soft-Tissue Sarcoma: A Randomised Controlled Phase 3 Trial
Judson, van der Graaf·Lancet Oncol·2014·1,181 citations
Soft Tissue and Visceral Sarcomas: Esmo–euracan–genturis Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up
Gronchi, Stacchiotti·Annals of Oncology·2021·901 citations
Denosumab in Patients with Giant-Cell Tumour of Bone: An Open-Label, Phase 2 Study.
Thomas, Jun·Lancet·2010·708 citations
Histotype-Tailored Neoadjuvant Chemotherapy versus Standard Chemotherapy in Patients with High-Risk Soft-Tissue Sarcomas (ISG-STS 1001): An International, Open-Label, Randomised, Controlled, Phase 3, Multicentre Trial.Citation only
Gronchi, Casali·Lancet Oncol·2017·500 citations
Bone Sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up.Citation only
Strauss, Stacchiotti·Ann Oncol·2021·492 citations
Pexidartinib versus Placebo for Advanced Tenosynovial Giant Cell Tumour (ENLIVEN): A Randomised Phase 3 Trial
Tap, Wagner·Lancet·2019·480 citations
Prognostic Factors Influencing Progression-Free Survival Determined from a Series of Sporadic Desmoid Tumors: A Wait-And-See Policy According to Tumor Presentation.Citation only
Salas, Coindre·J Clin Oncol·2011·386 citations
Improved Survival Using Specialized Multidisciplinary Board in Sarcoma Patients.Citation only
Blay, Le Cesne·Ann Oncol·2017·384 citations
Denosumab in Patients with Giant-Cell Tumour of Bone: A Multicentre, Open-Label, Phase 2 Study.Citation only
Chawla, Palmerini·Lancet Oncol·2019·257 citations
Surgical versus Non-Surgical Approach in Primary Desmoid-Type Fibromatosis Patients: A Nationwide Prospective Cohort from the French Sarcoma GroupCitation only
Penel, Blay·Eur J Cancer·2017·188 citations
Giant Cell Tumour of Bone in the Denosumab Era.Citation only
van der Heijden, Gelderblom·Eur J Cancer·2017·174 citations
Results of a Phase II Pilot Study of Moderate Dose Radiotherapy for Inoperable Desmoid-Type Fibromatosis--An EORTC STBSG and ROG Study (EORTC 62991-22998).Citation only
Keus, van der Graaf·Ann Oncol·2013·138 citations
Vimseltinib versus Placebo for Tenosynovial Giant Cell Tumour (MOTION): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.Citation only
Gelderblom, Tap·Lancet·2024·80 citations
Malignancy in Giant Cell Tumor of Bone: Analysis of an Open-Label Phase 2 Study of Denosumab.Citation only
Palmerini, Picci·BMC Cancer·2021·39 citations